These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31248604)

  • 1. Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
    Ranasinghe WKB; Reichard CA; Chapin BF
    Eur Urol; 2019 Nov; 76(5):543-545. PubMed ID: 31248604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
    Xu L; Pachynski RK
    Curr Urol Rep; 2018 Aug; 19(10):79. PubMed ID: 30105573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
    Weiner AB; Nettey OS; Morgans AK
    Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
    Hammerer P; Manka L
    Urologe A; 2019 Oct; 58(10):1185-1197. PubMed ID: 31127324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
    Wenzel M; Hoeh B; Chun FKH; Mandel P
    Urologie; 2023 Apr; 62(4):360-368. PubMed ID: 36763112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
    Messina C; Messina M; Boccardo F
    Eur Urol; 2018 Jan; 73(1):147-148. PubMed ID: 28801126
    [No Abstract]   [Full Text] [Related]  

  • 8. Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.
    Baston C; Preda A; Guler-Margaritis SS; Sinescu I; Gingu C
    Curr Opin Urol; 2020 Jul; 30(4):576-583. PubMed ID: 32427630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
    Francini E; Gray KP; Xie W; Shaw GK; Valença L; Bernard B; Albiges L; Harshman LC; Kantoff PW; Taplin ME; Sweeney CJ
    Prostate; 2018 Sep; 78(12):889-895. PubMed ID: 29707790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care?
    Joseph N; Anjanappa M; Choudhury A
    Cancer J; 2020; 26(1):83-86. PubMed ID: 31977390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolving options in metastatic castration-sensitive prostate cancer.
    Hamilou Z
    Curr Opin Support Palliat Care; 2020 Sep; 14(3):270-275. PubMed ID: 32701855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or….
    Barata PC; Sartor AO
    Cancer; 2019 Jun; 125(11):1777-1788. PubMed ID: 30933324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment concepts for primary oligometastatic prostate cancer].
    Knipper S; Graefen M; Hadaschik B; Wiegel T
    Urologe A; 2020 Jun; 59(6):659-664. PubMed ID: 32274541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
    Ito T; Grant L; Duckham BR; Ribbands AJ; Gater A
    Adv Ther; 2018 Dec; 35(12):2186-2200. PubMed ID: 30415297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer.
    Vicier C; Feng FY; Fizazi K
    Eur Urol Focus; 2019 Mar; 5(2):168-170. PubMed ID: 30745118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of hormone-naïve metastatic prostate cancer.
    Hamilou Z; Saad F; Fizazi K
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):334-338. PubMed ID: 30015691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.
    Hahn AW; Stenehjem DD; Alex AB; Gill DM; Cheng HH; Kessler ER; Chittoria N; Twardowski P; Vaishampayan U; Agarwal N
    Urol Oncol; 2019 Jun; 37(6):352.e19-352.e24. PubMed ID: 30770300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial.
    Abdel-Rahman O; Cheung WY
    Clin Genitourin Cancer; 2018 Dec; 16(6):466-472. PubMed ID: 30098982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone naïve metastatic prostate cancer: How to treat it?
    Østergren PB; Ternov KK; Jensen CFS; Jakobsen H; Lindberg H; Sønksen J; Fode M
    Arch Esp Urol; 2019 Mar; 72(2):192-202. PubMed ID: 30855021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.